IGF-1 LR3

Mechanism

A modified version of IGF-1 (Insulin-like Growth Factor 1) that lasts much longer in the body than natural IGF-1. It promotes muscle cell growth and division, and helps shuttle nutrients into muscle cells. The modification (Arg3 substitution + 13-amino acid extension) prevents it from being neutralized by IGF-binding proteins.

Effects

## IGF-1 LR3 — System-by-System Effects ### Musculoskeletal System (Primary Use in Practice) - **Muscle hypertrophy**: IGF-1 LR3 is a modified form of IGF-1 with an arginine substitution at position 3 and a 13-amino acid extension at the N-terminus. These modifications prevent binding to IGF binding proteins (IGFBPs), resulting in dramatically longer half-life (~20-30 hours vs. ~15 minutes for native IGF-1) and enhanced bioactivity. [Tier 1 — well-characterized analog] - **Satellite cell activation**: IGF-1 activates muscle satellite cells (muscle stem cells), promoting their proliferation and fusion with existing muscle fibers. This is how IGF-1 drives actual muscle fiber hyperplasia (new fibers), not just hypertrophy (bigger fibers). [Tier 1 — established muscle biology] - **Protein synthesis**: Activates the PI3K/Akt/mTOR pathway, the central anabolic signaling cascade for muscle protein synthesis. [Tier 1] - **Anti-catabolic**: Inhibits muscle protein breakdown through suppression of the ubiquitin-proteasome pathway and autophagy. [Tier 1] - **Connective tissue**: Promotes collagen synthesis and connective tissue repair. [Tier 2] ### Metabolic System - **Insulin-like effects**: IGF-1 LR3 binds the insulin receptor (weakly) in addition to the IGF-1 receptor. At high doses, it can cause hypoglycemia through insulin-like glucose uptake effects. This is a significant safety concern. [Tier 1] - **Glucose uptake**: Enhances muscle glucose uptake, which can lower blood sugar. Users must be aware of hypoglycemia risk, especially with concurrent insulin use. [Tier 1] - **Fat metabolism**: Some evidence for lipolytic effects, though this is less pronounced than the anabolic muscle effects. [Tier 2] - **Nutrient partitioning**: At proper doses, IGF-1 LR3 may improve nutrient partitioning — directing calories toward muscle growth rather than fat storage. This is the theoretical basis for its appeal in bodybuilding. [Tier 2-3] ### Cell Proliferation (The Cancer Concern) - **Growth promotion**: IGF-1 is one of the most potent mitogenic (cell growth-promoting) factors in the body. It promotes proliferation of virtually all cell types, including potentially cancerous ones. [Tier 1] - **Cancer epidemiology**: Elevated IGF-1 levels are associated with increased risk of several cancers (prostate, breast, colorectal). This is from observational epidemiology with IGF-1 levels within the normal range. Supraphysiological IGF-1 from exogenous LR3 is completely unstudied for cancer risk. [Tier 1 for epidemiology] - **Tumor promotion vs. initiation**: IGF-1 likely promotes the growth of existing tumors rather than initiating new ones. This means pre-existing occult cancers could be accelerated. [Tier 2] - **Acromegaly comparison**: Acromegaly (excess GH/IGF-1) is associated with increased cancer risk, particularly colorectal cancer. Exogenous IGF-1 LR3 mimics some aspects of this biology. [Tier 1] ### Neurological System - **Neuroprotection**: IGF-1 has neuroprotective and neurotrophic properties. It supports neuronal survival, synaptic plasticity, and myelination. [Tier 2] - **Cognitive function**: GH/IGF-1 axis decline contributes to age-related cognitive decline. However, supraphysiological levels are not studied for cognitive benefit. [Tier 2] ### Organ Growth - **Organomegaly risk**: IGF-1 promotes growth of internal organs. GH abuse-related organ growth (intestinal hypertrophy, cardiac enlargement) is partly IGF-1-mediated. [Tier 1 for GH/IGF-1 biology] - **Cardiac hypertrophy**: Prolonged supraphysiological IGF-1 could promote left ventricular hypertrophy. [Tier 2]

Practitioner Guide

## IGF-1 LR3 — Practitioner Guide ### Clinical Profile IGF-1 LR3 (Long R3 IGF-1) is a synthetic analog of insulin-like growth factor 1 with enhanced potency and duration of action. It is used in the bodybuilding/performance community for muscle growth. It is NOT FDA-approved for any indication (mecasermin/Increlex is the approved recombinant IGF-1, different from LR3). ### The Bodybuilding Community Reality Check #### What the Community Claims - "IGF-1 LR3 causes muscle hyperplasia — new muscle fibers that are permanent" - "The closest thing to HGH results without the cost" - "Site-specific muscle growth when injected locally" - These claims have some basis in biology but are significantly overstated. #### What Actually Happens (Realistic Observations) - **Modest muscle gains**: Experienced users report 3-7 lbs of lean mass over a 4-6 week course. Some of this is glycogen and water, not pure contractile tissue. - **Muscle fullness**: The most consistent report is improved muscle "fullness" — a pumped, volumized appearance. This is partly glycogen and water from insulin-like effects. - **Strength**: Modest strength improvements, less dramatic than anabolic steroids. - **Recovery**: Improved recovery between workouts is commonly reported. This may be the most reliable benefit. - **Fat loss**: Some users report concurrent fat loss, but this is inconsistent and confounded by training/diet. - **Site injections**: Many users inject IGF-1 LR3 into specific muscles believing it causes localized growth. Evidence for this is weak — LR3's long half-life means it goes systemic regardless of injection site. Native IGF-1 (short half-life) has a better theoretical basis for local effects. - **Diminishing returns**: Effects tend to plateau after 4-6 weeks. Extended use beyond this does not proportionally increase results and increases risk. #### Common Community Protocols - **Dose**: 20-60mcg/day SC or IM. Most start at 20mcg and increase. Experienced users sometimes go to 80-100mcg but risk escalates. - **Duration**: 4-6 weeks on, 4-6 weeks off. Some cycle 4 weeks on/2 weeks off. - **Timing**: Post-workout injection is most common. Some split doses (AM and post-workout). - **With GH**: Often combined with growth hormone. GH increases hepatic IGF-1 production; adding exogenous LR3 provides supraphysiological levels. This combination significantly increases risk. - **With insulin**: Combining IGF-1 LR3 with insulin is extremely dangerous. Both lower blood sugar. Hypoglycemic coma and death have occurred. THIS COMBINATION SHOULD BE STRONGLY DISCOURAGED. ### Why Experienced Practitioners Approach Cautiously 1. **Cancer risk is NOT theoretical**: The epidemiological association between elevated IGF-1 and cancer risk is real (Tier 1 evidence). Supraphysiological IGF-1 from exogenous LR3 pushes levels far above what the epidemiological data covers. Anyone with a family history of cancer, previous cancer, or elevated PSA should absolutely not use this. 2. **Hypoglycemia can be fatal**: IGF-1 LR3 lowers blood sugar. Combined with training (which also lowers blood sugar) and especially with insulin, this can cause life-threatening hypoglycemia. Multiple deaths have been attributed to IGF-1/insulin combinations in the bodybuilding community. 3. **Organ growth**: Prolonged supraphysiological IGF-1 promotes growth of internal organs, including the heart, intestines, and potentially tumors. The "GH gut" (distended abdomen) seen in elite bodybuilders is partly IGF-1-mediated intestinal hypertrophy. 4. **No safety data**: Zero controlled human safety studies for IGF-1 LR3 at any dose. All safety information is extrapolated from IGF-1 physiology, acromegaly data, and community anecdote. 5. **Modest results relative to risk**: The muscle-building effects of IGF-1 LR3 are moderate at best. Testosterone, nandrolone, and other anabolic steroids produce more muscle growth with better-understood (though still significant) risk profiles. 6. **Product quality**: Like follistatin, IGF-1 LR3 is a complex protein vulnerable to degradation. Quality varies enormously across sources. ### If a Patient Insists on Using IGF-1 LR3 1. **Cancer screening first**: PSA, colonoscopy (if due), dermatologic exam, any age-appropriate cancer screenings. MUST be negative before proceeding. 2. **Baseline labs**: IGF-1 level, comprehensive metabolic panel, HbA1c, fasting insulin, fasting glucose, complete blood count, echocardiogram. 3. **Absolute contraindications**: Personal or strong family history of cancer, active diabetes, cardiac hypertrophy, acromegaly features. 4. **Dose**: Start low (20mcg/day). Do NOT exceed 40-50mcg without compelling reason. 5. **Duration**: Maximum 4-6 weeks. Mandatory break of equal or longer duration. 6. **Hypoglycemia prevention**: Carry glucose tablets. NEVER combine with exogenous insulin. Eat within 30 minutes of injection. Monitor blood sugar during first week. 7. **Monitoring during use**: Weekly fasting glucose, watch for hypoglycemic symptoms (shakiness, confusion, sweating, weakness). 8. **Post-course**: Repeat IGF-1 level, metabolic panel, and cancer screening markers. 9. **Ongoing monitoring**: Annual cancer screening for any patient who has used supraphysiological IGF-1. 10. **Document the conversation**: Ensure the patient understands the cancer, hypoglycemia, and organ growth risks. Document informed consent.

Dosing Protocols

Contraindications & Cautions

• hard stop — Active cancer
  IGF-1 LR3 is a potent, long-acting IGF-1 analog with reduced IGFBP binding, resulting in dramatically increased free IGF-1 bioactivity. IGF-1 is one of the most potent known mitogens — it drives cell proliferation, inhibits apoptosis, and promotes angiogenesis. IGF-1 LR3 could powerfully accelerate tumor growth and metastasis.
  Action: Do not use in patients with any active cancer. This is one of the highest-risk peptides for cancer patients due to direct mitogenic mechanism.
• hard stop — Concurrent insulin use
  IGF-1 LR3 and insulin have synergistic hypoglycemic effects. IGF-1 LR3 binds insulin receptors while exogenous insulin provides additional glucose-lowering activity. This combination can cause severe, refractory, and potentially FATAL hypoglycemia.
  Action: Do not use IGF-1 LR3 concurrently with insulin. This combination is extremely dangerous. Hypoglycemic coma and death have been reported with IGF-1/insulin combinations.
• hard stop — Pregnancy
  No human safety data. Potent growth factor with mitogenic activity poses serious risk to fetal development.
  Action: Do not use during pregnancy. Absolutely contraindicated.
• hard stop — Breastfeeding
  No data on safety during lactation. Potent growth factor exposure in nursing infant is unacceptable.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  Potent growth factor. May cause disproportionate growth and metabolic disruption in developing physiology.
  Action: Do not provide to individuals under 18.
• requires physician — Diabetes
  IGF-1 LR3 has potent hypoglycemic effects — it binds insulin receptors and promotes glucose uptake independently of insulin. In diabetic patients on glucose-lowering medications, severe and potentially fatal hypoglycemia can occur.
  Action: Requires physician supervision. Frequent blood glucose monitoring essential. Diabetes medication dose reduction may be needed. Educate on hypoglycemia emergency management.
• requires physician — GH secretagogues (MK-677, GHRP-2, GHRP-6, etc.)
  Combining IGF-1 LR3 with GH secretagogues creates additive/synergistic growth factor signaling. Increased risk of hypoglycemia, edema, and disproportionate tissue growth.
  Action: Requires physician supervision. Monitor blood glucose, edema, and organ growth markers. Not recommended without medical oversight.

Evidence

• Insulin-like growth factor 1 and analogs with extended half-lives

  Francis GL, Ross M, Ballard FJ, Milner SJ, Senn C, McNeil KA, Wallace JC, King R, Wells JR (1992) — Journal of Molecular Endocrinology — PMID: 1390313

  IGF-1 LR3 (Long-Arg3 IGF-1) was engineered with an N-terminal extension and arginine substitution at position 3, dramatically reducing binding to IGF-binding proteins (IGFBPs). This results in ~3-fold greater potency than native IGF-1 in vitro due to higher free (bioavailable) IGF-1 at target tissues. The analog retains full IGF-1 receptor binding and activation.

  emerging

Stacks featuring this peptide

Research Summary

## IGF-1 LR3 — Research Summary ### Tier 1 (Strong Clinical Evidence) - **IGF-1 biology**: IGF-1 signaling through PI3K/Akt/mTOR is one of the most thoroughly studied growth factor pathways in biology. Thousands of publications. - **Cancer epidemiology**: Multiple large prospective studies (EPIC, NHS, HPFS) associate higher circulating IGF-1 with increased cancer risk for prostate, breast, and colorectal cancer. Well-replicated. - **Acromegaly outcomes**: Excess GH/IGF-1 in acromegaly is associated with cardiomyopathy, organomegaly, diabetes, and increased cancer risk. This provides the closest human model for supraphysiological IGF-1 effects. - **LR3 pharmacology**: The LR3 modifications (Arg3 substitution, N-terminal extension) that prevent IGFBP binding and extend half-life are well-characterized biochemically. - **Hypoglycemia risk**: IGF-1's insulin-like glucose-lowering effect is well-documented in clinical IGF-1 studies (mecasermin/Increlex). - **Mecasermin (Increlex)**: FDA-approved recombinant IGF-1 for severe primary IGF-1 deficiency. Provides clinical safety data for IGF-1 replacement (not LR3, not supraphysiological doses). ### Tier 2 (Moderate Evidence) - **Muscle satellite cell activation**: IGF-1 activation of satellite cells is well-documented in cell culture and animal models. Translation to exogenous LR3 injection protocols is assumed but not proven. - **Muscle hyperplasia**: Animal models show IGF-1 can induce true muscle fiber hyperplasia, not just hypertrophy. Whether this occurs in adult humans with SC IGF-1 LR3 injections is unproven. - **Neuroprotection**: Preclinical data supporting IGF-1 neuroprotection. Clinical application for exogenous LR3 is unexplored. - **Cardiac hypertrophy risk**: Animal data showing IGF-1 promotes cardiac growth. Clinical significance for periodic SC LR3 use is uncertain. ### Tier 3 (Emerging/Anecdotal) - **Bodybuilding community experience**: Widespread anecdotal use. Reports suggest modest muscle and recovery benefits with significant variability. - **Safety observations**: No controlled safety data. Community reports of hypoglycemia are common. Cancer outcomes cannot be tracked in this population. - **Site-specific injection**: No evidence that site-specific injection of LR3 produces localized muscle growth (unlike theoretical basis for native IGF-1). - **Product quality**: Independent testing shows significant variability in commercial IGF-1 LR3 products. ### Key Research Gaps - Zero controlled human studies of IGF-1 LR3 for muscle growth or any indication - Cancer risk of supraphysiological exogenous IGF-1 is completely unknown - Cardiac safety of periodic supraphysiological IGF-1 exposure is unknown - Whether SC/IM injection of LR3 produces the satellite cell activation and hyperplasia seen in preclinical studies - Long-term health outcomes of former IGF-1 LR3 users - Dose-response relationship in humans for both efficacy and adverse effects